Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kiniksa Pharmaceuticals International, plc (KNSA : NSDQ)

• Company Description    Kiniksa Pharmaceuticals International plc is a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa Pharmaceuticals International plc is based in LONDON. Number of Employees: 315

• Price / Volume Information    Yesterday's Closing Price: $37.10 Daily Weekly Monthly 20 Day Moving Average: 411,524 shares Shares Outstanding: 74.11 (millions) Market Capitalization: $2,749.41 (millions) Beta: 0.20 52 Week High: $37.25 52 Week Low: $17.82 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 11.48% 9.52% 12 Week 32.83% 20.66% Year To Date 87.56% 67.06%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 23 Old Bond Street Floor 3 - London,X0 WIS 4PZ GBR ph: 781-431-9100 fax: - ir@kiniksa.com http://www.kiniksa.com

• General Corporate Information    Officers Sanj K. Patel - Chief Executive Officer and Chairman Mark Ragosa - Chief Financial Officer Michael R. Megna - Vice President Stephen R. Biggar - Director Felix J. Baker - Director Peer Information Kiniksa Pharmaceuticals International, plc (CORR.) Kiniksa Pharmaceuticals International, plc (RSPI) Kiniksa Pharmaceuticals International, plc (CGXP) Kiniksa Pharmaceuticals International, plc (BGEN) Kiniksa Pharmaceuticals International, plc (GTBP) Kiniksa Pharmaceuticals International, plc (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G52694109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/04/25 Share - Related Items Shares Outstanding: 74.11 Most Recent Split Date: (:1) Beta: 0.20 Market Capitalization: $2,749.41 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.31 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $1.03 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/25

• Fundamental Ratios P/E Current FY Estimate: 36.02 Trailing 12 Months: 927.50 PEG Ratio: - Price Ratios Price/Book: 5.55 Price/Cash Flow: - Price / Sales: 5.19 EPS Growth vs. Year Ago Period: 483.33% vs. Previous Quarter: 109.09% Sales Growth vs. Year Ago Period: 44.34% vs. Previous Quarter: 13.80% ROE 06/30/25 - 1.05 03/31/25 - -3.83 12/31/24 - -9.92 ROA 06/30/25 - 0.80 03/31/25 - -2.98 12/31/24 - -7.86 Current Ratio 06/30/25 - 3.57 03/31/25 - 3.66 12/31/24 - 3.30 Quick Ratio 06/30/25 - 3.16 03/31/25 - 3.43 12/31/24 - 3.04 Operating Margin 06/30/25 - 0.90 03/31/25 - -3.52 12/31/24 - -10.20 Net Margin 06/30/25 - 0.90 03/31/25 - -3.52 12/31/24 - -10.20 Pre-Tax Margin 06/30/25 - 2.69 03/31/25 - -1.31 12/31/24 - -8.54 Book Value 06/30/25 - 6.68 03/31/25 - 6.27 12/31/24 - 6.60 Inventory Turnover 06/30/25 - 2.38 03/31/25 - 2.44 12/31/24 - 2.08 Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©